“…Wikwanikit has several concerns about our report on the effectiveness of treating the host response of patients with Ebola virus disease using a combination of a statin (atorvastatin) and an angiotensin receptor blocker (ARB) (irbesartan) ( 1 , 26 ). First, not all of the endothelial damage in Ebola described by Baskerville et al in 1985 was caused by thrombotic events.…”